Blood antibodies may predict heart failure risk after viral infection
NCT ID NCT06742008
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is looking at whether certain antibodies in the blood can help predict which patients with acute viral myocarditis (heart inflammation caused by a virus) will go on to develop dilated cardiomyopathy (a weakened, enlarged heart). Researchers will measure two specific antibodies in 300 patients and follow them over time to see who develops heart problems. The goal is to find a way to identify high-risk patients early so they can be monitored or treated more closely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Viral myocarditis (VMC) is an inflammation of the myocardium caused by viral infections. Common viruses include coxsackievirus, adenovirus, cytomegalovirus, and influenza virus. The prognosis for patients with Acute viral myocarditis (AVMC) varies widely, with most patients recovering with treatment, but some progressing to dilated cardiomyopathy (DCM). Studies have shown that about one-third of patients with AVMC eventually develop DCM, and that the immune response following viral infection is key to the development of DCM in AVMC. Following viral infection, specific antigenic determinants within cardiomyocytes are exposed to the immune system, triggering an autoimmune response against the myocardium, leading to damage and dysfunction of cardiomyocytes.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Meets diagnostic criteria for VMC 2. Clinical symptoms present for no more than 30 days 3. Age ≥ 18 years and ≤ 75 years 4. Subjects or their legal guardians are fully informed of the nature and risks of the study, participate voluntarily, and sign an informed consent form. Exclusion Criteria: 1. Serious uncontrolled infection at enrolment ("uncontrolled" is defined as signs and symptoms of infection that persist without improvement despite antimicrobial or other treatment) 2. Uncontrolled active bleeding at enrollment 3. Systemic autoimmune disease such as systemic lupus erythematosus or diagnosed immunodeficiency disease at enrollment 4. Pregnancy or breastfeeding 5. Combination of serious diseases affecting survival, such as tumors, with a life expectancy shorter than 3 months 6. Patients with poor compliance who are unable to complete the full course of the study 7. Other conditions (e.g., overstimulation, sensitivity, cognitive impairment, mental illness, or substance abuse/addiction) that, in the judgment of the investigator, may increase the risk to the subject or interfere with the clinical study and judgment of the results.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Viral myocarditis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
RECRUITINGWuhan, Hubei, 430000, China